Profile

Personal Information:
Name: Jimin Shao, Ph.D.
Date of Birth: October 26, 1962
Citizenship: P.R.China
Affiliation and Professional Position：
Professor, Pathophysiology, Molecular and Cellular Oncology
Executive director, Center for Cancer Research
Vice Chair, Department of Pathology and Pathophysiology,
Associate Dean, School of Basic Medical Sciences, Zhejiang University.

Contact Information:
Tel: +86-571-88208209
Email: shaojimin@zju.edu.cn
Homepage: http://mypage.zju.edu.cn/0092566
Laboratory Address: Research Building, Room C339
Zhejiang University School of Medicine, 866 Yu-Hang-Tang Rd., Hangzhou 310058, P.R.China

Education and Employment:
(1) 2006-now：Professor, School of Basic Medical Sciences, Zhejiang University, Hangzhou, China;
(2) 2002-2005：Visiting Scientist, Dept. of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, CA, USA;
(3) 1998-2001：Associate Professor, Medical Microbiology, Zhejiang University, Hangzhou, China;
(4) 2001：Ph.D., Medical Oncology, Zhejiang University Cancer institute, Hangzhou, China.

Professional societies:
(1) Member of Executive committee, Chinese Association of Pathophysiology
(2) Member of Executive committee, Physiology Association of Zhejiang Province
(3) Member, American Association for Cancer Research
(4) Member, International Association for Pathophysiology

Research Interests and Projects:
(1) Molecular mechanisms of chemical mutagenesis and carcinogenesis;
(2) Protein modification, signal transduction, and epigenetics in inflammation and cancer;
(3) Structure and function of anti-cancer drug targets and novel drug discovery.
We take multidisciplinary approaches to disclose molecular mechanisms of chemical carcinogenesis, identify new biomarkers and therapeutic targets for cancer prevention, diagnosis, and treatment, and design and develop novel drugs for cancer chemotherapy. Our team consists of researchers with diverse expertises that include bioinformatics, medicinal chemistry, biochemistry, molecular & cell biology, pharmacology, and medical sciences. Our ongoing projects are supported by grants from the Natural Science Foundation of China, the 863 and 973 National Key Research Programs of China, the Scientific Research Foundations of Ministry of Education and Ministry of Human Resources for the Returned Overseas Chinese Scholars, and etc.

Representative Publications:
（1）Qi H, Zhu H, Lou M, Fan Y, Liu H, Shen J, Li Z, Lv X, Shan J, Zhu L, Chin YE*, Shao J*. Interferon regulatory factor1 transactivates the expression of human DNA polymerase η in response to the carcinogen N-methyl-N’-nitro-N-nitrosoguanidine. J Biol Chem. 2012;287(16):12622-33. （*Corresponding author）
（2）Zhu H, Fan Y, Shen J, Qi H, Shao J*. Characterization of human DNA polymerase κ promoter in response to benzo[a]pyrene diol epoxide. Environmental Toxicology and Pharmacology, 2012; 33(2): 205-211.
（3）Wang Q, Jiang H, Fan Y, Huang X, Shen J, Qi H, Li Q, Lu X, Shao J*. Phosphorylation of the α-subunit of the Eukaryotic Initiation Factor-2 (eIF2α) alleviates benzo(a)pyrene-7,8-diol-9,10-epoxide induced cell cycle arrest and apoptosis in human cells. Environmental Toxicology and Pharmacology 2011;31(1):18-24.
（4）Zhu H, Fan Y, Jiang H, Shen J, Qi H, Mei R, Shao J*. Response of human DNA polymerase promoter to N-methyl-N/'-nitro-N-nitrosoguanidine. Environmental Toxicology and Pharmacology 2010;29 (1) : 79–86.
（5）Lu X#, Shao J#, Li H, Yu Y. Temporal gene expression changes induced by a low concentration of benzo[a]pyrene diol epoxide in a normal human cell line. Mutation Research 2010;684(1-2):74-80. (# Co-first authors).
（6）Zhu L, Zhou B, Chen X, Jiang H, Shao J*, Yen Y*. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase. Biochemical Pharmacology 2009;78:1178-1185.
（7）Lu X#, Shao J#, Li H, Yu Y. Early whole-genome transcriptional response induced by benzo(a)pyrene diol epoxide in a normal human cell line. Genomics 2009; 93:332-342.
（8）Li H#, Shao J#, Lu X, Gao Z, Yu Y. Identification of early responsive genes in human amnion epithelial FL cells induced by N-methyl-N/'-nitro-N-nitrosoguanidine using oligonucleotide microarray and quantitative real-time RT-PCR approaches. Mutation Research 2008;644(1-2):1-10.
（9）Shao J, Zhou B, Zhu L, Di Bilio A, Yen Y. A Ferrous-triapine Complex Mediates Formation of Reactive Oxygen Species That Inactivate Human Ribonucleotide Reductase. Molecular Cancer Therapeutics 2006;5(3): 586-592.
（10）Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide Reductase Inhitiors and future drug design. Current Cancer Drug Targets 2006;6(5):409-431.
（11）Qiu W, Zhou B, Darwish D, Shao J, Yen Y. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits. Biochemical and Biophysical Research Communications 2006;340(2):428-434.
（12）Zhu L, Yen Y, Shao J, Qi C, Yen C, Luo J, Zhou B. Fibroblast Growth Factor Receptor 3 Up-Regulates Vascular Endothelial Growth Factor Expression In L6 Cells. International Journal of Pharmacology 2006;2(3):324-330.
（13）Shao J, Zhou B, Zhu L, Di Bilio AJ, Su L, Yuan Y, Ren S, Lien EJ, Shih J, Yen Y. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. Biochemical Pharmacology 2005; 69: 627–634.
（14）Zhou B, Shao J, Su L, Yuan Y, Qi C, Yen Y. A Dityrosyl-diiron Radical Cofactor Center is Essential for Human Ribonucleotide Reductases. Molecular Cancer Therapeutics 2005; 4(12): 1830-6.
（15）Zhu L, Somlo G, Zhou B, Shao J, Bedell V, lovak ML, Liu X, Luo J, Yen Y. Fibroblast Growth Factor Receptor 3 inhibited by short-hairpin RNAs Leads to Apoptosis in Multiple Myeloma. Molecular Cancer Therapeutics 2005; 4(5):787-98.
（16）Shao J, Zhou B, Zhu L, Qiu W, Yuan Y, Xi B, Yen Y. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Research 2004; 64: 1-6.

International Conferences
（1）Shao J (Invited speaker). p53R2, a novel p53-inducible gene involved in DNA damage repair. “Second International Conference on Frontiers in Biomedical and Environmental Health Sciences: DNA Repair and Cancer Biology”, Aril 2008, Hangzhou, China.
（2）Shao J (Invited speaker). Different inhibitory properties of hydroxyurea and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone for two forms of human ribonucleotide reductase. “The 5th International Congress of Pathophysiology”, June 2006, Beijing, China.
（3）Shao J, Zhou B, Zhu L, Di Bilio AJ, Su L, Yuan YC, Yen Y. Characterization of the interacting mechanisms between Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and the small subunits of human Ribonucleotide Reductase. Proceedings of the American Association for Cancer Research 2005, USA.
（4）Zhu L, Somlo G, Zhou B, Shao J, Clarke K, Hughes A, Luo J, Yen Y. Function of wild type fibroblast growth factor receptor 3 and Y373C, K650E mutants in human lymphoma U937 cells. Proceedings of the American Association for Cancer Research 2005, USA.
（5）Shao J, Zhou B, Zhu L, Di Bilio AJ, Su L, Lien EJ, Shih J, Yen Y. In vitro high throughput screening assay of novel inhibitors with reconstituted ribonucleotide reductase holoenzyme. Proceedings of the American Association for Cancer Research 2004, USA.
（6）Zhu L, Somlo G, Zhou B, Shao J, Shih J, Luo J, Yen Y. shRNA-induced inhibition of Fibroblast Growth Factor Receptor 3 in t(4;14) translocated multiple myeloma cells. Proceedings of the American Association for Cancer Research 2004, USA.